A 2-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation with Optimized T-Cell Dosing: Early Immune Reconstitution Leads to Better Outcomes

Authors

Sameh Gaballa, Thomas Jefferson University HospitalFollow
Onder Alpdogan, Thomas Jefferson University HospitalFollow
Matthew Carabasi, Thomas Jefferson UniversityFollow
Joanne Filicko, Thomas Jefferson UniversityFollow
Margaret Kasner, Thomas Jefferson UniversityFollow
Ubaldo E. Martinez-Outshoorn, MD, Thomas Jefferson UniversityFollow
John L Wagner, Thomas Jefferson UniversityFollow
Mark Weiss, Thomas Jefferson UniversityFollow
Neal Flomenberg, Thomas Jefferson UniversityFollow
Delores Grosso, Thomas Jefferson UniversityFollow

Document Type

Abstract

Publication Date

2-16-2013

Comments

Track: BMT Tandem "Scientific" Meeting Saturday, February 16, 2013, 4:45 PM-6:45 PM Ballroom A-D (Salt Palace Convention Center)

Abstract

We developed a 2-step approach to myeloablative haploidentical HSCT in which patients receive a large fixed dose of cyclophosphamide (CY)-tolerized T cells separately frm the HSC infusion in the hopes of accelerating post HSCT immune reconstitution (IR). The uniformity of the T cell dosing facilitates comparison of patients without (low risk) and with (high risk) active malignancy at HSCT to ascertain the impact of disease status at HSCT on IR with fewer confounding effects from conditioning or T cell dosing.

Recommended Citation

Gaballa, Sameh; Alpdogan, Onder; Carabasi, Matthew; Filicko, Joanne; Kasner, Margaret; Martinez-Outshoorn, MD, Ubaldo E.; Wagner, John L; Weiss, Mark; Flomenberg, Neal; and Grosso, Delores, "A 2-Step Approach to Myeloablative Haploidentical Stem Cell Transplantation with Optimized T-Cell Dosing: Early Immune Reconstitution Leads to Better Outcomes" (2013). Department of Medical Oncology Faculty Papers. Paper 16.
https://jdc.jefferson.edu/medoncfp/16